KMTS President and CEO Brian Daniel Webster Sells $443K of Stock

Kestra Medical Technologies, Ltd. (NasdaqGS: KMTS) President and Chief Executive Officer Brian Daniel Webster sold 15,000 shares of company stock on October 20, 2026. According to a Form 4 filing with the SEC, the transaction was executed at a price of $29.56 per share, for a total value of $443,389.50.

KMTS Kestra Medical Technologies, Ltd.

$28.32 ▲ +16.11% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside Brian Daniel Webster's Kestra Medical Trade

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Webster directly holds 445,215 shares of the medical device maker, marking a 3.26% decrease in his personal stake.

Other Institutional Activity in Kestra Medical

Other major institutional investors adjusted their positions in Kestra Medical earlier in the year. Bain Capital Investors Llc held 25,172,338 shares valued at $712,880,604. Andera Partners maintained 2,728,679 shares worth $77,276,188. Yu Fan held 2,282,519 shares valued at $64,640,937. Brown Advisory Inc. grew its holdings by 185,303 shares, ending with 1,909,056 shares worth about $54,064,465 after a 10.8% increase. Alliancebernstein L.P. lifted its stake by 157,649 shares, finishing with 1,477,992 shares valued at about $41,856,732 following an 11.9% increase.

Kestra Medical Technologies, Ltd. Stock Up 3.7%

Shares of Kestra Medical recently traded around $28.32 as of October 22, 2026, remaining close to their 52-week high of $30.00. The stock trades about 7.1% above its 50-day moving average of $26.45 and roughly 19.8% above its 200-day moving average of $23.64. The company carries a market capitalization of roughly $1.69 billion.

Recent Earnings

Kestra Medical reported $106,726,000 in trailing twelve month revenue with a year-over-year revenue growth rate of 59.9%. The company posted a trailing twelve month net loss with an earnings per share of -$2.67. Its net profit margin stood at -140.4%, and return on equity was -73.7%. The company's next earnings report is scheduled for release on December 14, 2026.

Insider Buying and Selling at Kestra Medical Technologies, Ltd.

Several other insiders completed transactions prior to Webster's sale. Director Mary Kay Ladone sold 3,908 shares at $25.20 for $98,464 on September 8, 2026. Director and 10% owner Jeffrey Lawrence Schwartz sold 3,890 shares at $25.18 for $97,942 on the same day. Director Elizabeth Kwo sold 4,010 shares at $24.26 for $97,268 on September 21, 2026. Director Raymond W Cohen sold 3,330 shares at $29.28 for $97,504 on September 30, 2026.

Analysts Set New Price Targets

Wall Street firms have actively covered the medical technology company. Oppenheimer initiated coverage with a Perform rating on July 21, 2026. JP Morgan initiated coverage with an Overweight rating and a $30.00 price target on August 10, 2026. BTIG reiterated a Buy rating with a $32.00 price target on September 2, 2026, and again on September 15, 2026. Evercore ISI Group initiated coverage with an Outperform rating and a $34.00 price target on October 20, 2026. The stock currently holds a strong buy consensus recommendation among eight analysts, with an average target price of $30.75.

About Kestra Medical

Headquartered in Kirkland, Washington, Kestra Medical Technologies builds wearable cardiovascular monitoring and digital health tools designed to support patient interventions. The healthcare firm employs 443 people and focuses on expanding cardiac care solutions as it prepares for its late-year financial update.

Bottom Line

Investors continue to monitor insider activity alongside institutional holdings as Kestra Medical moves toward its next earnings update in December. The company maintains strong analyst backing even as executive leadership trims portions of its equity holdings through planned transactions.